Bispecific Chimeric Antigen Receptors Targeting CD20 and Bcma
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application PCT/US2024/022317, filed Mar 29, 2024. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 12,311,022 | Bispecific Chimeric Antigen Receptors Targeting CD20 and Bcma In force · High confidence | Abelzeta Inc. | In force | High confidence | ||
| US 12,458,667 | Bispecific Chimeric Antigen Receptors Targeting CD20 and Bcma In force · High confidence | Abelzeta Inc. | In force | High confidence | ||
| US 12,751,973 | Bispecific Chimeric Antigen Receptors Targeting CD20 and Bcma In force · Low confidence | Abelzeta Inc. | In force | Low confidence | ||
| Application 19/188,511 | Bispecific Chimeric Antigen Receptors Targeting CD20 and Bcma Pending Not granted | Abelzeta Inc. | Pending | Not granted | ||
| Application 19/348,065 | Bispecific Chimeric Antigen Receptors Targeting CD20 and Bcma Pending Not granted | Abelzeta Inc. | Pending | Not granted | ||
| Application 19/356,548 | Bispecific Chimeric Antigen Receptors Targeting CD20 and Bcma Pending Not granted | Abelzeta Inc. | Pending | Not granted | ||
| Application 19/356,595 | Bispecific Chimeric Antigen Receptors Targeting CD20 and Bcma Pending Not granted | Abelzeta Inc. | Pending | Not granted |
7 of 7 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Abelzeta Inc..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.